Dr. Sathishkumar Selvaraj

Employment

• Archeron Group Lead Investigator
  2021 - Present
• Syngene International Ltd Research Investigator
  2019 - 2021
• The Peter Doherty Institute for Infection and Immunity Research Officer
  2017 - 2018

Education

• National Centre for Cell Science PhD
  2011 - 2016
• Bharathidasan University Master of Science
  2006 - 2008
• S.K.S.S. Arts College Bachelor of Science
  2003 - 2006

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• Peptidoglycan-treated tumor antigen-pulsed dendritic cells impart complete resistance against tumor rechallenge.
  Clinical and experimental immunology 2020 DOI: 10.1111/cei.13468
  +Save
• 17th International Congress of Immunology, 19–23 October 2019, Beijing, China
  European Journal of Immunology 2019 DOI: 10.1002/eji.201970400
  +Save
• DAMP-TLR-cytokine axis dictates the fate of tumor.
  Cytokine 2017 DOI: 10.1016/j.cyto.2017.10.004
  +Save
• Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.
  Journal of immunology (Baltimore, Md. : 1950) 2014 DOI: 10.4049/jimmunol.1400672
  +Save
• Toll-like receptors and CD40 modulate each other's expression affectingLeishmania majorinfection
  Clinical & Experimental Immunology 2014 DOI: 10.1111/cei.12264
  +Save
• Anti-VEGF antibody enhances the antitumor effect of CD40.
  International journal of cancer 2014 DOI: 10.1002/ijc.28833
  +Save
• Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection.
  BMC microbiology 2013 DOI: 10.1186/1471-2180-13-236
  +Save
• Prostaglandin E₂ receptors have differential effects on Leishmania major infection.
  Parasite immunology 2013 DOI: 10.1111/pim.12011
  +Save